Target Name: CCN1
NCBI ID: G3491
Other Name(s): CCN family member 1 | cysteine-rich heparin-binding protein 61 | GIG1 | CCN1_HUMAN | CTGF-2 | IBP-10 | protein CYR61 | IGFBP10 | IGFBP-10 | Insulin-like growth factor-binding protein 10 | IGF-binding protein 10 | Protein GIG1 | Cysteine-rich angiogenic inducer 61 | cysteine rich angiogenic inducer 61 | cellular communication network factor 1 | cysteine-rich, anigogenic inducer, 61 | Cellular communication network factor 1 | insulin-like growth factor-binding protein 10 | Connective tissue growth factor-2 | CYR61 | Cysteine-rich heparin-binding protein 61

CCN1: A Potential Drug Target and Biomarker for Neurodegenerative Disorders

Neurodegenerative disorders are a group of progressive diseases that affect the nervous system, leading to a range of symptoms and loss of cognitive and motor function. These disorders have a significant impact on quality of life and can also be fatal, making them a major public health issue. The identification of potential drug targets and biomarkers for neurodegenerative disorders is a promising approach to developing new treatments. In this article, we will explore CCN1, a protein that is expressed in the brain and has been linked to several neurodegenerative disorders, as a potential drug target and biomarker.

CCN1: Background and Expression

CCN1, or neurotrophic factor WF-A, is a transmembrane protein that is expressed in the brain and has been shown to play a role in the development and progression of several neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. CCN1 is a member of the CCN family, which is characterized by the presence of a unique transmembrane domain and a characteristic N-terminus.

Expression of CCN1 has been observed in various tissues and organs, including the brain, where it is primarily expressed in the peri-synaptic region of dendrites, the site of synaptic transmission. In the brain, CCN1 is expressed in the basal ganglia, where it is involved in the regulation of movement and coordination.

Potential Drug Target and Biomarker

The identification of potential drug targets and biomarkers for neurodegenerative disorders is an important step in the development of new treatments. CCN1 has been shown to play a role in the development of neurodegenerative disorders, and targeting its activity may be a promising approach to treating these disorders.

One potential drug target for CCN1 is the inhibition of its activity, as this can potentially reduce the progression of neurodegenerative disorders. Several studies have shown that inhibitors of CCN1 have been effective in animal models of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease.

In addition to its potential as a drug target, CCN1 has also been identified as a potential biomarker for neurodegenerative disorders. The expression of CCN1 has been observed in the brains of individuals with neurodegenerative disorders, and its levels have been shown to be altered in the brains of individuals with these disorders compared to age-matched control individuals. This suggests that CCN1 may be a useful biomarker for the diagnosis and monitoring of neurodegenerative disorders.

Conclusion

In conclusion, CCN1 is a protein that has been linked to several neurodegenerative disorders and has the potential to be a drug target and biomarker for these disorders. The inhibition of CCN1's activity or its expression may be a promising approach to treating neurodegenerative disorders. Further research is needed to fully understand the role of CCN1 in neurodegenerative disorders and to develop effective treatments.

Protein Name: Cellular Communication Network Factor 1

Functions: Promotes cell proliferation, chemotaxis, angiogenesis and cell adhesion. Appears to play a role in wound healing by up-regulating, in skin fibroblasts, the expression of a number of genes involved in angiogenesis, inflammation and matrix remodeling including VEGA-A, VEGA-C, MMP1, MMP3, TIMP1, uPA, PAI-1 and integrins alpha-3 and alpha-5. CCN1-mediated gene regulation is dependent on heparin-binding. Down-regulates the expression of alpha-1 and alpha-2 subunits of collagen type-1. Promotes cell adhesion and adhesive signaling through integrin alpha-6/beta-1, cell migration through integrin alpha-v/beta-5 and cell proliferation through integrin alpha-v/beta-3

More Common Targets

CCN2 | CCN3 | CCN4 | CCN5 | CCN6 | CCNA1 | CCNA2 | CCNB1 | CCNB1IP1 | CCNB2 | CCNB2P1 | CCNB3 | CCNC | CCND1 | CCND2 | CCND2-AS1 | CCND3 | CCNDBP1 | CCNE1 | CCNE2 | CCNF | CCNG1 | CCNG2 | CCNH | CCNI | CCNI2 | CCNJ | CCNJL | CCNK | CCNL1 | CCNL2 | CCNO | CCNP | CCNQ | CCNQP1 | CCNT1 | CCNT2 | CCNT2-AS1 | CCNT2P1 | CCNY | CCNYL1 | CCNYL2 | CCP110 | CCPG1 | CCR1 | CCR10 | CCR12P | CCR2 | CCR3 | CCR4 | CCR4-NOT transcription complex | CCR5 | CCR5AS | CCR6 | CCR7 | CCR8 | CCR9 | CCRL2 | CCS | CCSAP | CCSER1 | CCSER2 | CCT2 | CCT3 | CCT4 | CCT5 | CCT6A | CCT6B | CCT6P1 | CCT6P3 | CCT7 | CCT8 | CCT8L1P | CCT8L2 | CCT8P1 | CCZ1 | CCZ1B | CCZ1P-OR7E38P | CD101 | CD101-AS1 | CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1